JP2001328948A - Solid preparation containing hydroxypropyl cellulose having low substitution degree and method for producing the same - Google Patents

Solid preparation containing hydroxypropyl cellulose having low substitution degree and method for producing the same

Info

Publication number
JP2001328948A
JP2001328948A JP2001074044A JP2001074044A JP2001328948A JP 2001328948 A JP2001328948 A JP 2001328948A JP 2001074044 A JP2001074044 A JP 2001074044A JP 2001074044 A JP2001074044 A JP 2001074044A JP 2001328948 A JP2001328948 A JP 2001328948A
Authority
JP
Japan
Prior art keywords
solid preparation
bulk density
sugar
low
average particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001074044A
Other languages
Japanese (ja)
Other versions
JP3698652B2 (en
Inventor
Fumie Tanno
史枝 丹野
Sakae Ohara
栄 尾原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shin Etsu Chemical Co Ltd
Original Assignee
Shin Etsu Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Etsu Chemical Co Ltd filed Critical Shin Etsu Chemical Co Ltd
Priority to JP2001074044A priority Critical patent/JP3698652B2/en
Publication of JP2001328948A publication Critical patent/JP2001328948A/en
Application granted granted Critical
Publication of JP3698652B2 publication Critical patent/JP3698652B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide an easily producible solid preparation quickly disintegrating in the mouth by swallowing together with the saliva in the mouth or a small amount of water and having a moderate strength to keep the form during the production and distribution stages and provide a method for the production of the solid preparation. SOLUTION: The solid preparation contains a sugar or a sugar alcohol and a hydroxypropyl cellulose having low substitution degree, a loose bulk density of >=0.40 g/ml and a tight bulk density of >=0.60 g/ml. The present invention further provides a method for the production of the solid preparation. More particularly, the present invention provides a solid preparation containing a sugar or a sugar alcohol and a hydroxypropyl cellulose having low substitution degree and a volume-average particle diameter of <=25 μm measured by dry laser diffraction method and produced by crushing a hydroxypropyl cellulose having low substitution degree, a loose bulk density of >=0.40 g/ml, a tight bulk density of >=0.60 g/ml and a volume-average particle diameter of >=30 μm and a method for the production of the solid preparation.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、口腔内の唾液又は
少量の水により速やかに口腔内で崩壊する固形製剤に関
するものである。
TECHNICAL FIELD The present invention relates to a solid preparation which is rapidly disintegrated in the oral cavity by saliva or a small amount of water in the oral cavity.

【0002】[0002]

【従来の技術】近年、嚥下能力が低い高齢者や小児など
の患者のために、易服用・易投与な固形製剤が望まれて
いる。具体的には、口腔内崩壊性製剤、ゼリー状製剤、
ペースト状製剤等が挙げられるが、特に口腔内崩壊錠剤
は水なしであるいは少量の水により服用することが可能
であり、簡便にかつ比較的容易に服用することができ高
齢者や小児などに適した剤形となり得る。
2. Description of the Related Art In recent years, a solid preparation that can be easily taken and administered has been desired for patients such as the elderly and children having a low swallowing ability. Specifically, orally disintegrating preparations, jelly-like preparations,
Examples include paste-form preparations. Particularly, orally disintegrating tablets can be taken without water or with a small amount of water, and can be taken easily and relatively easily, and are suitable for elderly people and children. Dosage form.

【0003】これまでにも様々な口腔内崩壊性製剤が提
案されている。例えば、特公昭62−50445号公報
には薬物、ゼラチンなどのポリマー水溶液をPTP(Pr
essThrough Package)ポケットに充填して凍結乾燥する
ことにより製造される口腔内崩壊性錠剤及びその製造方
法が提案されている。しかしながら、この方法では、特
殊な製造工程が必要であり、得られる錠剤の強度が小さ
く取り扱いに問題があった。
[0003] Various orally disintegrating preparations have been proposed so far. For example, Japanese Patent Publication No. Sho 62-50445 discloses that an aqueous solution of a polymer such as a drug or gelatin is prepared using PTP (Pr).
An orally disintegrating tablet produced by filling a essThrough Package) pocket and freeze-drying, and a method for producing the same have been proposed. However, this method requires a special production process, and the strength of the obtained tablet is small, and there is a problem in handling.

【0004】また、特開平5−271054号公報で
は、薬物、糖類及び適当な水分を含む練合物を低圧で打
錠した後、乾燥した口腔内崩壊錠剤及びその製造方法が
提案されているが、打錠の際、臼・杵等に練合物が付着
しやすく、製造工程での水分管理が困難であるといった
問題があるため、大量生産には適していない。
Japanese Patent Application Laid-Open No. Hei 5-27054 proposes an orally disintegrating tablet which is obtained by compressing a kneaded product containing a drug, a saccharide and an appropriate water at a low pressure, and then drying the tablet. At the time of tableting, there is a problem that the kneaded material easily adheres to a mortar, a punch, and the like, and it is difficult to control the moisture in the manufacturing process, so that it is not suitable for mass production.

【0005】一方、特開平8―291051号公報及び
特開平9−48726号公報には、糖類・糖アルコール
類、水溶性結合剤と薬物等を混合して低圧で打錠した
後、錠剤強度の増大のために加湿下で錠剤を湿潤させ、
次いで乾燥した口腔内崩壊性錠剤及びその製造方法が提
案されているが、製造工程が多段階になること、加湿工
程で錠剤の外観が変化し商品価値が損なわれる、さらに
湿度に不安定な薬物や潮解性を示す薬物には適さない等
の問題があった。
[0005] On the other hand, JP-A-8-291051 and JP-A-9-48726 disclose that a saccharide / sugar alcohol, a water-soluble binder and a drug are mixed and tableted at a low pressure, and the tablet strength is reduced. Wet the tablet under humidification for growth,
Then, a dry orally disintegrating tablet and a method for producing the same have been proposed. However, the manufacturing process is multi-stage, the appearance of the tablet is changed in the humidification process, and the commercial value is impaired. There is a problem that it is not suitable for drugs that show deliquescence.

【0006】こうした特殊な製剤技術を必要とせず、一
般的な設備で口腔内崩壊性製剤を調製する方法も幾つか
提案されている。特開平9−71523号公報では、薬
物と崩壊剤として低置換度ヒドロキシプロピルセルロー
ス、賦形剤として結晶セルロース及び滑沢剤からなる混
合物を低圧で打錠した口腔内崩壊錠剤が提案されてい
る。しかし、セルロース系やポリビニルピロリドン系の
添加剤を多く使用するため、錠剤の崩壊性、溶解性、舌
触り、味において実用上劣るという欠点が生じる。
[0006] Several methods have been proposed for preparing orally disintegrating preparations using general equipment without the need for such special preparation techniques. Japanese Patent Application Laid-Open No. 9-71523 proposes an orally disintegrating tablet prepared by tableting a mixture of a drug, a low-substituted hydroxypropylcellulose as a disintegrant, a crystalline cellulose as an excipient and a lubricant at a low pressure. However, since a large amount of cellulose-based or polyvinylpyrrolidone-based additives are used, there is a drawback that the tablet is practically inferior in disintegration, solubility, texture, and taste.

【0007】特開平11−43429号公報には、薬
物、糖及び置換度の限定された低置換度ヒドロキシプロ
ピルセルロースからなる口腔内崩壊錠剤が提案されてい
るが、錠剤の舌触り、味の改善は充分ではなかった。
JP-A-11-43429 proposes an orally disintegrating tablet comprising a drug, a sugar and a low-substituted hydroxypropylcellulose having a limited degree of substitution. However, the tablet has improved tongue and taste. It was not enough.

【0008】[0008]

【発明が解決しようとする課題】本発明は、口腔内の唾
液又は少量の水と共に服用することにより、口腔内で速
やかに崩壊し、製造工程が容易で、かつ製造時や流通過
程において成形性を保持しうる適度な強度を有する固形
製剤及びその製造方法を提供することを目的とする。
DISCLOSURE OF THE INVENTION The present invention is intended to disintegrate quickly in the oral cavity by taking it with saliva or a small amount of water in the oral cavity, to facilitate the production process, and to improve the moldability during production and distribution. It is an object of the present invention to provide a solid preparation having an appropriate strength capable of retaining a solid preparation and a method for producing the same.

【0009】[0009]

【課題を解決するための手段】本発明者らは、ゆるめ嵩
密度が0.40g/ml以上で、かつ固め嵩密度が0.
60g/ml以上である低置換度ヒドロキシプロピルセル
ロース及び糖・糖アルコールを含有する固形製剤を用い
ることにより、固形製剤に適度な強度を与えるとともに
に口腔内で味の不快感を感じることなく、速やかに薬物
が崩壊することを見出し、本発明をなすに至ったもので
ある。即ち、ゆるめ嵩密度が0.40g/ml以上で、
かつ固め嵩密度が0.60g/ml以上である低置換度ヒ
ドロキシプロピルセルロース及び糖・糖アルコールを含
有することを特徴とする固形製剤及びその製造方法を提
供する。また、ゆるめ嵩密度が0.40g/ml以上
で、かつ固め嵩密度が0.60g/ml以上で、かつ乾式
レーザー回折法による体積平均粒子径が30ミクロン以
上である低置換度ヒドロキシプロピルセルロースを粉砕
して得られる体積平均粒子径が25ミクロン以下の低置
換度ヒドロキシプロピルセルロース及び糖・糖アルコー
ルを含有することを特徴とする固形製剤及びその製造方
法を提供する。
Means for Solving the Problems The present inventors have found that the loose bulk density is 0.40 g / ml or more and the hardened bulk density is 0.4 g / ml.
By using a solid preparation containing a low-substituted hydroxypropylcellulose of 60 g / ml or more and a sugar / sugar alcohol, the solid preparation is given an appropriate strength, and at the same time, without feeling unpleasant taste in the oral cavity, It has been found that the drug disintegrates in the present invention, and the present invention has been accomplished. That is, the loose bulk density is 0.40 g / ml or more,
A solid preparation comprising low-substituted hydroxypropylcellulose having a bulk density of 0.60 g / ml or more and sugar / sugar alcohol, and a method for producing the same. A low-substituted hydroxypropylcellulose having a loose bulk density of 0.40 g / ml or more, a hardened bulk density of 0.60 g / ml or more, and a volume average particle diameter of 30 μm or more measured by a dry laser diffraction method is used. Provided is a solid preparation characterized by containing a low-substituted hydroxypropylcellulose having a volume average particle diameter of 25 μm or less obtained by pulverization and sugar / sugar alcohol, and a method for producing the same.

【0010】[0010]

【発明の実施の形態】本発明における「ゆるめ嵩密度」
とは、疎充填の状態の嵩密度をいい、直径5.03c
m、高さ5.03cm(容積100ml)の円筒容器
(材質:ステンレス)へ試料をJISの24メッシュの
篩を通して、上方(23cm)から均一に供給し、上面
をすり切って秤量することによって測定される。一方、
「固め嵩密度」とは、これにタッピングを加えて密充填
にした場合の嵩密度をいう。ここで、タッピングとは、
試料を充填した容器を一定の高さから繰り返し落下させ
て底部に軽い衝撃を与え、試料を密充填にする操作をい
う。実際には、ゆるめ嵩密度を測定する際、上面をすり
切って秤量した後、さらにこの容器の上にキャップ(下
記ホソカワミクロン社製パウダーテスターの備品)をは
め、この上縁まで粉体を加えてタップ高さ1.8cmの
タッピングを180回行う。終了後、キャップを外して
容器の上面で粉体をすり切って秤量し、この状態の嵩密
度を固め嵩密度とする。これらの操作は、ホソカワミク
ロン社製パウダーテスター(PT−D)を使用すること
により測定できる。
BEST MODE FOR CARRYING OUT THE INVENTION "Loose bulk density" in the present invention
Means the bulk density in a loosely packed state, having a diameter of 5.03c.
m, a sample is uniformly supplied from above (23 cm) through a JIS 24-mesh sieve into a cylindrical container (material: stainless steel) having a height of 5.03 cm (volume: 100 ml), and is measured by wiping the upper surface and weighing. Is done. on the other hand,
The term “solid bulk density” refers to the bulk density when the material is densely packed by tapping. Here, tapping is
This refers to the operation of repeatedly dropping a container filled with a sample from a certain height to give a light impact to the bottom and to tightly fill the sample. In practice, when measuring the loose bulk density, after weighing the top of the container, put a cap (supplied by Hosokawa Micron's powder tester) on this container, and add powder to the upper edge. Tapping is performed 180 times with a tap height of 1.8 cm. After completion, the cap is removed and the powder is ground and weighed on the upper surface of the container, and the bulk density in this state is hardened to obtain the bulk density. These operations can be measured by using a powder tester (PT-D) manufactured by Hosokawa Micron Corporation.

【0011】本発明の低置換度ヒドロキシプロピルセル
ロースは、ゆるめ嵩密度が0.40g/ml以上、かつ
固め嵩密度が0.60g/ml以上の低置換度ヒドロキ
シプロピルセルロース、好ましくはこの嵩密度を有する
乾式レーザー回折法による平均体積粒子径が30ミクロ
ン以上の低置換度ヒドロキシプロピルセルロースを粉砕
するなどして得られるものである。なお、粉砕工程は、
常法に従って行われ、例えばボールミル、ハンマーミ
ル、ナイフミル、ジェットミルなどの粉砕機を用いるこ
とができる。本発明にいう乾式レーザー回折法とは、例
えばドイツSympatec社のHELOS装置を用いた方法のよう
に、圧縮空気で粉体サンプルを噴出させたものにレーザ
ー光を照射し、その回折強度により体積平均径を測定す
る方法をいう。体積平均粒径は、例えば「改訂増補粉体
物性図説」粉体工学会・日本粉体工業技術協会編、日経
技術図書、1985年、第88頁に記載されているよう
に、式{Σ(nD3)/Σn}1/3を用いて計算される。
式中、Dは粒子の直径、nはその直径の粒子数、Σnは
全粒子数を表す。
The low-substituted hydroxypropylcellulose of the present invention has a low-substituted hydroxypropylcellulose having a loose bulk density of at least 0.40 g / ml and a hardened bulk density of at least 0.60 g / ml. It is obtained by pulverizing a low-substituted hydroxypropylcellulose having an average volume particle diameter of 30 μm or more by a dry laser diffraction method. In addition, the grinding process
It is performed according to a conventional method, and for example, a pulverizer such as a ball mill, a hammer mill, a knife mill, and a jet mill can be used. The dry laser diffraction method referred to in the present invention is, for example, a method using a HELOS device manufactured by Sympatec of Germany. A method for measuring the diameter. The volume average particle size can be calculated by the formula {(volume average particle size) as described in, for example, "Revised Augmented Powder Physical Properties Illustration", edited by Japan Society of Powder Technology and Japan Powder Industry Technical Association, Nikkei Technical Book, 1985, page 88. nD 3 ) / {n} 1/3 .
In the formula, D is the diameter of the particle, n is the number of particles of that diameter, and Δn is the total number of particles.

【0012】本発明に用いる低置換度ヒドロキシプロピ
ルセルロースは、セルロースエーテルの一種であり、結
合剤として汎用されるヒドロキシプロピルセルロースと
類似するが、その性質を異にする。前者と後者の本質的
な違いは、ヒドロキシプロポキシル基の含有量にあり、
その値は、前者が5〜16.0重量%であるのに対し、
後者が53.4〜77.5重量%である。この値は、日
本薬局方に収載されている方法で測定し、その範囲は日
本薬局方「低置換度ヒドロキシプロピルセルロース」の
モノグラフで明確に規定されている。即ち、低置換度ヒ
ドロキシプロピルセルロースのヒドロキシプロポキシル
基の含有量は、5.0〜16.0重量%である。
The low-substituted hydroxypropylcellulose used in the present invention is a kind of cellulose ether and is similar to hydroxypropylcellulose generally used as a binder, but has different properties. The essential difference between the former and the latter lies in the content of hydroxypropoxyl groups,
The value of the former is 5 to 16.0% by weight,
The latter is 53.4 to 77.5% by weight. This value is measured by the method described in the Japanese Pharmacopoeia, and its range is clearly defined in the monograph of Japanese Pharmacopoeia "Low-substituted hydroxypropylcellulose". That is, the content of the hydroxypropoxyl group in the low-substituted hydroxypropylcellulose is 5.0 to 16.0% by weight.

【0013】ゆるめ嵩密度が0.40g/ml以上、か
つ固め嵩密度が0.60g/ml以上の低置換度ヒドロ
キシプロピルセルロースは、以下に示す方法により製造
することができる。すなわち、パルプをアルカリ溶液に
浸漬して、アルカリセルロースとし、これを酸化プロピ
レンと反応させる。この後の工程において、生成物を水
又はアルカリ性に調節した水に投入して、完全溶解さ
せ、ほとんど均一な透明なスラリー状にしてから、塩酸
で中和して析出された低置換度ヒドロキシプロピルセル
ロースを回収後、水で洗浄し乾燥して粉砕する。ここで
いう完全溶解状態とは、生成物がその形状をほぼ完全に
失う状態を意味する。すなわち、完全に透明になること
はもとより、不透明のスラリー状態や3リットルのスラ
リー中に5〜10個の割合で生成物小塊の残留が認めら
れる程度も含む。溶解した後の状態は、高粘度のスラリ
ー状であり、ニーダーなどの撹拌力の強い練合機が必要
である。この後、塩酸等の酸で中和することにより、低
置換度ヒドロキシプロピルセルロースが析出し、このも
のを回収して洗浄、乾燥、粉砕して製品とする。
The low-substituted hydroxypropylcellulose having a loose bulk density of 0.40 g / ml or more and a hardened bulk density of 0.60 g / ml or more can be produced by the following method. That is, the pulp is immersed in an alkaline solution to form alkali cellulose, which is reacted with propylene oxide. In the subsequent step, the product is put into water or water adjusted to alkaline, completely dissolved, and turned into an almost uniform transparent slurry, and then neutralized with hydrochloric acid to precipitate a low-substituted hydroxypropyl. After collecting the cellulose, it is washed with water, dried and pulverized. The term "completely dissolved state" as used herein means a state in which the product almost completely loses its shape. That is, it includes not only complete transparency but also an opaque slurry state and the degree to which 5 to 10 small product lumps remain in a 3 liter slurry. The state after dissolution is a slurry of high viscosity and requires a kneading machine such as a kneader with a strong stirring power. Thereafter, the mixture is neutralized with an acid such as hydrochloric acid to precipitate hydroxypropylcellulose having a low degree of substitution, which is collected, washed, dried and pulverized to obtain a product.

【0014】本発明の好ましい態様として、ゆるめ嵩密
度が0.40g/ml以上(より好ましくは0.40g
/ml以上0.60g/ml未満)、かつ固め嵩密度が
0.60g/ml以上(より好ましくは0.60g/m
l以上0.85g/ml未満)、かつ乾式レーザー回折
法による平均体積粒子径が30ミクロン以上(より好ま
しくは30ミクロン以上200ミクロン以下)の低置換
度ヒドロキシプロピルセルロースを粉砕して、該回折法
による体積平均粒子径が25ミクロン以下の低置換度ヒ
ドロキシプロピルセルロースが用いられる。このように
して得られた低置換度ヒドロキシプロピルセルロース
は、ゆるめ嵩密度が0.29g/ml以上(より好まし
くは0.29g/ml以上0.55g/ml未満)、固
め嵩密度が0.55g/ml以上(より好ましくは0.
55g/ml以上0.85g/ml未満)であることが
好ましい。
In a preferred embodiment of the present invention, the loose bulk density is 0.40 g / ml or more (more preferably 0.40 g / ml).
/ Ml or more and less than 0.60 g / ml) and a consolidated bulk density of 0.60 g / ml or more (more preferably 0.60 g / m
1 to less than 0.85 g / ml) and a low-substituted hydroxypropylcellulose having an average volume particle size of 30 μm or more (more preferably 30 μm or more and 200 μm or less) determined by dry laser diffraction. Low-substituted hydroxypropylcellulose having a volume average particle size of 25 microns or less. The low-substituted hydroxypropylcellulose thus obtained has a loose bulk density of 0.29 g / ml or more (more preferably 0.29 g / ml or more and less than 0.55 g / ml) and a hardened bulk density of 0.55 g. / Ml or more (more preferably 0.
55 g / ml or more and less than 0.85 g / ml).

【0015】本発明における低置換度ヒドロキシプロピ
ルセルロースの添加量は、固形製剤100重量部中に1
〜99重量部、好ましくは、5〜50重量部である。低
置換度ヒドロキシプロピルセルロースの添加量が1重量
部未満だと、錠剤の強度が不十分で取り扱いが困難とな
り、99重量部を超えると錠剤強度は得られるが、口腔
内での崩壊が遅延するおそれがある。
The amount of the low-substituted hydroxypropylcellulose used in the present invention is 1 per 100 parts by weight of the solid preparation.
-99 parts by weight, preferably 5-50 parts by weight. If the amount of low-substituted hydroxypropylcellulose is less than 1 part by weight, tablet strength is insufficient and handling becomes difficult. If it exceeds 99 parts by weight, tablet strength is obtained, but disintegration in the oral cavity is delayed. There is a risk.

【0016】本発明において、糖・糖アルコールとは、
糖アルコールを含めた広い意味の糖である。糖は、糖類
のうち水溶性で甘味をもつものの総称であり単糖類と大
多数の少糖類が含まれ、多糖類も加水分解によって糖に
帰着するため、糖類に含まれる。糖アルコールは、糖の
カルボニル基が還元された鎖上の多価アルコールを指
し、類似の性質をもつ環式糖アルコール(シクリトー
ル)も含む。本発明において、糖・糖アルコールとして
は、好ましくは、エリスリトール、ソルビトール、トレ
ハロース、キシリトール、マンニトール、グルコース、
白糖などが挙げられ、特に好ましくは、エリスリトール
又はソルビトール、トレハロース、キシリトールが挙げ
られ、これらは、単独又は2種以上混合して使用するこ
ともできる。これらの糖・糖アルコールは、結晶又は粉
末で用いられるが、特に平均粒子径が500ミクロン以
下のものを用いると、成形性、崩壊性、舌触りの点で優
れた特性を示す。
In the present invention, the sugar / sugar alcohol is
It is a sugar in a broad sense, including sugar alcohols. Sugar is a general term for water-soluble and sweet saccharides, and includes monosaccharides and most oligosaccharides. Polysaccharides are also included in saccharides because they are converted into sugars by hydrolysis. Sugar alcohol refers to a polyhydric alcohol on the chain in which the carbonyl group of the sugar has been reduced, and also includes cyclic sugar alcohols (cyclitols) having similar properties. In the present invention, the sugar / sugar alcohol is preferably erythritol, sorbitol, trehalose, xylitol, mannitol, glucose,
Sucrose and the like are particularly preferred, and erythritol or sorbitol, trehalose, and xylitol are particularly preferred. These can be used alone or in combination of two or more. These sugars / sugar alcohols are used in the form of crystals or powders. When the sugars / sugar alcohols have an average particle diameter of 500 μm or less, they exhibit excellent properties in terms of moldability, disintegration, and texture.

【0017】糖・糖アルコールの添加量は、固形製剤1
00重量部中に1〜99重量部、好ましくは10〜90
重量部である。糖・糖アルコールの添加量が、1重量部
未満だと口腔内での崩壊に時間を要し、99重量部を超
えると充分な製剤の強度が得られなくなるおそれがあ
る。
The amount of the sugar / sugar alcohol to be added is as follows:
1 to 99 parts by weight, preferably 10 to 90 parts by weight in 00 parts by weight
Parts by weight. If the amount of the sugar or sugar alcohol is less than 1 part by weight, it takes time to disintegrate in the oral cavity, and if it exceeds 99 parts by weight, sufficient strength of the preparation may not be obtained.

【0018】また、本発明の固形製剤に加える主成分
は、医薬品であれば解熱鎮痛剤、抗生物質、抗炎症剤、
ビタミンや栄養物など特に限定はされない。さらに、他
の成分として例えば滑沢剤、結合剤、安定化剤、着色
剤、矯味剤などを添加しても良い。
The main components to be added to the solid preparation of the present invention are antipyretic analgesics, antibiotics, anti-inflammatory agents, and pharmaceuticals.
There is no particular limitation on vitamins and nutrition. Further, as other components, for example, a lubricant, a binder, a stabilizer, a coloring agent, a flavoring agent, and the like may be added.

【0019】本発明の固形製剤の製造方法については、
前記の組成物を混合して直接打錠あるいは乾式打錠する
か、乾式造粒、流動層造粒あるいは湿式造粒等いずれの
方法も適用される。また、錠剤を製造するための打錠方
法は、一般に錠剤を成形又は造粒するための装置を用い
て行われ、例えば単発打錠機、ロータリー打錠機、タブ
レッティングテスターなどが挙げられる。打錠の際の成
形圧力は、通常50〜300MPa、好ましくは80〜
200MPaである。成形圧力が50MPaより低いと
錠剤硬度が不足し取り扱いが困難となり、300MPa
より高いと崩壊が遅延する場合がある。
Regarding the method for producing the solid preparation of the present invention,
Any method such as mixing the above composition and directly tableting or dry tableting, dry granulation, fluidized bed granulation or wet granulation can be applied. A tableting method for producing tablets is generally performed using a device for forming or granulating tablets, and examples thereof include a single-shot tableting machine, a rotary tableting machine, and a tableting tester. The molding pressure during tableting is usually 50 to 300 MPa, preferably 80 to 300 MPa.
It is 200 MPa. If the molding pressure is lower than 50 MPa, tablet hardness becomes insufficient and handling becomes difficult, and 300 MPa
Higher values may delay disintegration.

【0020】上記のようにして製造された本発明の固形
製剤、特に口腔内崩壊錠剤は口腔内での崩壊性に優れ、
かつ適度な成形性(強度)を保持する。すなわち、本発
明の固形製剤の口腔内崩壊時間(健康な成人の口腔内の
唾液で錠剤が完全に崩壊するまでの時間)は、通常1〜
60秒、好ましくは1〜40秒、さらに好ましくは1〜
30秒程度である。また、錠剤硬度(錠剤硬度計によ
る)は、通常2〜15kgf好ましくは3〜10kgf
程度である。
The solid preparation of the present invention, particularly an orally disintegrating tablet produced as described above, has excellent disintegration in the oral cavity,
In addition, it maintains an appropriate formability (strength). That is, the oral disintegration time of the solid preparation of the present invention (the time required for the tablet to completely disintegrate in the oral cavity of a healthy adult) is usually 1 to 1.
60 seconds, preferably 1 to 40 seconds, more preferably 1 to
It is about 30 seconds. The tablet hardness (based on a tablet hardness tester) is usually 2 to 15 kgf, preferably 3 to 10 kgf.
It is about.

【0021】本発明における固形製剤には、錠剤、顆粒
剤、細粒剤、カプセル剤などが含まれる。
The solid preparation of the present invention includes tablets, granules, fine granules, capsules and the like.

【0022】[0022]

【実施例】以下に本発明の実施例及び比較例を示すが、
本発明はこれら実施例の内容のみに限定されるものでは
ない。 実施例1 エリスリトール(日研化学社製)を乳鉢で粉砕し、目開
き355ミクロンの篩で篩下した粉体を70重量部、本
発明の低置換度ヒドロキシプロピルセルロース(乾式レ
ーザー法での体積平均粒子径が47ミクロン、ゆるめ嵩
密度0.47g/ml、固め嵩密度0.69g/ml、
ヒドロキシプロポキシル基含有量11.0重量%)30
重量部を混合後、この混合粉末に対して0.5重量%の
割合でステアリン酸マグネシウムを配合し、単発打錠機
(三共パイオテク社製タブレッティングテスター)を用
いて、打錠圧100MPaで11mmφ、1錠480m
gの固形製剤を得た。
EXAMPLES Examples and comparative examples of the present invention are shown below.
The present invention is not limited only to the contents of these examples. Example 1 Erythritol (manufactured by Niken Kagaku Co., Ltd.) was pulverized in a mortar, and 70 parts by weight of a powder sieved with a sieve having an opening of 355 μm was added to a low-substituted hydroxypropylcellulose of the present invention (volume by dry laser method). Average particle size 47 microns, loose bulk density 0.47 g / ml, hardened bulk density 0.69 g / ml,
(Hydroxypropoxyl group content 11.0% by weight) 30
After mixing the parts by weight, magnesium stearate was blended at a ratio of 0.5% by weight with respect to the mixed powder, and a single-shot tableting machine (Tabletting Tester manufactured by Sankyo Piotech Co., Ltd.) was used to obtain 11 mmφ at a compression pressure of 100 MPa. 480m per tablet
g of a solid preparation were obtained.

【0023】実施例2 エリスリトールを乳鉢で粉砕し、目開きを355ミクロ
ンの篩で篩下した粉体を70重量部、本発明の低置換度
ヒドロキシプロピルセルロース(実施例1の低置換度ヒ
ドロキシプロピルセルロースを微粉砕した:乾式レーザ
ー法での体積平均粒子径が16ミクロン)30重量部を
混合後、この混合粉末に対して0.5重量%の割合でス
テアリン酸マグネシウムを配合し、単発打錠機を用いて
打錠圧100MPaで11mmφ、1錠480mgの固
形製剤を得た。
Example 2 Erythritol was ground in a mortar, and 70 parts by weight of a powder sieved with a sieve having a mesh size of 355 μm was mixed with 70 parts by weight of the low-substituted hydroxypropylcellulose of the present invention (the low-substituted hydroxypropyl cellulose of Example 1). Cellulose was finely pulverized: volume average particle size by dry laser method was 16 microns) After mixing 30 parts by weight, magnesium stearate was blended at a ratio of 0.5% by weight with respect to the mixed powder, and single-shot tableting was performed. A tableting pressure of 100 MPa was used to obtain a solid preparation of 11 mmφ and 480 mg per tablet using a press.

【0024】実施例3 エリスリトールを乳鉢で粉砕し、目開き355ミクロン
の篩で篩下した粉体70重量部に、実施例1の低置換度
ヒドロキシプロピルセルロース30重量部を混合し、流
動層造粒機(パウレック社製マルチプレックスMP−0
1)を用いて、精製水を噴霧し、流動層造粒を行った。
続いて、得られた造粒末に対して0.5重量%の割合で
ステアリン酸マグネシウムを配合し、単発打錠機を用い
て打錠圧100MPaで11mmφ、1錠480mgの
固形製剤を得た。
Example 3 Erythritol was pulverized in a mortar, and 70 parts by weight of a powder sieved with a sieve having an opening of 355 microns was mixed with 30 parts by weight of the low-substituted hydroxypropylcellulose of Example 1 to obtain a fluidized bed. Granulator (Multiplex MP-0 manufactured by Powrex)
Purified water was sprayed using 1) to perform fluidized bed granulation.
Subsequently, magnesium stearate was blended at a ratio of 0.5% by weight with respect to the obtained granulated powder, and a single tableting machine was used to obtain a solid preparation of 11 mmφ at a compression pressure of 100 MPa and 480 mg per tablet. .

【0025】実施例4 エリスリトールを乳鉢で粉砕し、目開き355ミクロン
の篩で篩下した粉体70重量部に、実施例2の低置換度
ヒドロキシプロピルセルロース30重量部を混合し、流
動層造粒機(パウレック社製マルチプレックスMP−0
1)を用いて、精製水を噴霧し、流動層造粒を行った。
続いて、得られた造粒末に対して0.5重量%の割合で
ステアリン酸マグネシウムを配合し、単発打錠機を用い
て打錠圧100MPaで11mmφ、1錠480mgの
固形製剤を得た。
Example 4 Erythritol was pulverized in a mortar, and 70 parts by weight of a powder sieved with a sieve having an opening of 355 microns was mixed with 30 parts by weight of the low-substituted hydroxypropylcellulose of Example 2 to obtain a fluidized bed. Granulator (Multiplex MP-0 manufactured by Powrex)
Purified water was sprayed using 1) to perform fluidized bed granulation.
Subsequently, magnesium stearate was blended at a ratio of 0.5% by weight with respect to the obtained granulated powder, and a single tableting machine was used to obtain a solid preparation of 11 mmφ at a compression pressure of 100 MPa and 480 mg per tablet. .

【0026】実施例5 打錠圧を200MPaに変えた以外は、実施例4と同様
の方法で口腔内崩壊錠剤を得た。
Example 5 An orally disintegrating tablet was obtained in the same manner as in Example 4 except that the tableting pressure was changed to 200 MPa.

【0027】比較例1 エリスリトールを乳鉢で粉砕し、目開き355ミクロン
の篩で篩下した粉体に0.5重量%のステアリン酸マグ
ネシウムを配合し、単発打錠機を用いて打錠圧100M
Paで11mmφ、1錠480mgの固形製剤を得た。
Comparative Example 1 Erythritol was pulverized in a mortar, and powder sieved with a sieve having a mesh size of 355 μm was mixed with 0.5% by weight of magnesium stearate.
A solid preparation of 11 mmφ in Pa and 480 mg per tablet was obtained.

【0028】比較例2 エリスリトールを乳鉢で粉砕し、目開き355ミクロン
の篩で篩下した粉体70重量部に低置換度ヒドロキシプ
ロピルセルロース(信越化学工業社製LH―21、乾式
レーザー法での体積平均粒子径が37ミクロン、ゆるめ
嵩密度0.335g/ml固め嵩密度0.597g/m
l、ヒドロキシプロポキシル基含有量が10.9重量
%)30重量部を混合し、この混合粉末に対して0.5
重量%の割合でステアリン酸マグネシウムを配合し、単
発打錠機を用いて打錠圧100MPaで11mmφ、1
錠480mgの口腔内崩壊錠剤を得た。
Comparative Example 2 Erythritol was crushed in a mortar, and 70 parts by weight of a powder sieved with a sieve having an opening of 355 μm was mixed with low-substituted hydroxypropylcellulose (LH-21 manufactured by Shin-Etsu Chemical Co., Ltd., using a dry laser method). Volume average particle size is 37 microns, loose bulk density 0.335g / ml hardened bulk density 0.597g / m
1, 30 parts by weight of a hydroxypropoxyl group content of 10.9% by weight),
Magnesium stearate was blended at a ratio of 1% by weight, and a tableting pressure of 100 MPa was applied to a tablet of 11 mmφ,
A tablet 480 mg orally disintegrating tablet was obtained.

【0029】比較例3 エリスリトールを乳鉢で粉砕し、目開き355ミクロン
の篩で篩下した粉体を70重量部に比較例2の低置換度
ヒドロキシプロピルセルロース30重量部を混合し、精
製水を噴霧して流動層造粒を行った。続いて、得られた
造粒末に対して0.5重量%の割合でステアリン酸マグ
ネシウムを配合した後、単発打錠機にて打錠圧100M
Paで11mmφ、1錠480mgの口腔内崩壊錠剤を
得た。
Comparative Example 3 Erythritol was pulverized in a mortar, and 70 parts by weight of a powder sieved with a sieve having an opening of 355 μm was mixed with 30 parts by weight of the low-substituted hydroxypropylcellulose of Comparative Example 2 to obtain purified water. The fluidized bed granulation was performed by spraying. Subsequently, after mixing magnesium stearate at a ratio of 0.5% by weight with respect to the obtained granulated powder, a tableting pressure of 100 M was applied by a single tableting machine.
An orally disintegrating tablet of 11 mmφ in Pa and 480 mg per tablet was obtained.

【0030】比較例4 比較例3の低置換度ヒドロキシプロピルセルロースを
(信越化学工業社製LH−31、乾式レーザー法での体
積平均粒子径が17ミクロン、ゆるめ嵩密度0.323
g/ml固め嵩密度0.623g/ml、ヒドロキシプ
ロポキシル含有量が10.9重量%)に変えた以外は同
様の方法で、口腔内崩壊錠を得た。
Comparative Example 4 The low-substituted hydroxypropylcellulose of Comparative Example 3 was used (LH-31 manufactured by Shin-Etsu Chemical Co., Ltd., volume average particle diameter by dry laser method: 17 μm, loose bulk density: 0.323)
Orally disintegrating tablets were obtained in the same manner, except that the bulk density was 0.623 g / ml and the hydroxypropoxyl content was 10.9% by weight.

【0031】比較例5 比較例3の低置換度ヒドロキシプロピルセルロースを
(信越化学工業社製LH―32、乾式レーザー法での体
積平均粒子径が18ミクロン、ゆるめ嵩密度0.306
g/ml固め嵩密度0.582g/ml、ヒドロキシプ
ロポキシル基含有量が8.3重量%)に変えた以外は、
同様の方法で口腔内崩壊錠剤を得た。
COMPARATIVE EXAMPLE 5 The low-substituted hydroxypropylcellulose of Comparative Example 3 was used (LH-32 manufactured by Shin-Etsu Chemical Co., Ltd., volume average particle diameter by dry laser method: 18 μm, loose bulk density: 0.306)
g / ml consolidated bulk density 0.582 g / ml, with hydroxypropoxyl group content of 8.3% by weight)
An orally disintegrating tablet was obtained in the same manner.

【0032】実施例1〜5及び比較例1〜5の口腔内崩
壊錠剤の硬度と崩壊時間とを測定し、その結果を表1に
示す。なお、口腔内崩壊錠剤の硬度は、錠剤硬度計(エ
ルヴェカ硬度計)を用い、崩壊時間の測定には日本薬局
方崩壊試験機(試験液:水、37℃)を使用し、n=6
(nは試料数を表す。)で測定を行った。口腔内崩壊時
間は、健康な成人男女5人で試験し、口腔内で錠剤を噛
まずに軽く口に含んだ状態で、錠剤が完全に溶解又は崩
壊するまでの時間を測定し、平均値を算出した。また、
この時の服用感も併せて評価した。評価は、良好
(◎)、やや良好(○)、普通(△)、不良(×)の四
段階とした。表1の結果から、硬度と崩壊時間の関係に
おいて、本発明の固形製剤は、崩壊時間が速く、口腔内
の触感も良好なものが得られた。
The hardness and disintegration time of the orally disintegrating tablets of Examples 1 to 5 and Comparative Examples 1 to 5 were measured, and the results are shown in Table 1. The hardness of the orally disintegrating tablet was measured using a tablet hardness tester (Elveca hardness tester), and the disintegration time was measured using a Japanese Pharmacopoeia disintegration tester (test solution: water, 37 ° C.), n = 6.
(N represents the number of samples). Oral disintegration time is tested in five healthy adult males and females, and the time taken for the tablet to completely dissolve or disintegrate is measured with the tablet lightly contained in the mouth without chewing in the oral cavity, and the average value is calculated. Calculated. Also,
The feeling of taking at this time was also evaluated. The evaluation was made in four stages: good (◎), slightly good (○), normal (△), and poor (x). From the results shown in Table 1, in the relationship between the hardness and the disintegration time, it was found that the solid preparation of the present invention had a fast disintegration time and a good oral feel.

【0033】[0033]

【発明の効果】本発明の固形製剤によれば、成形性及び
崩壊性に優れた特徴を有するため、嚥下力の弱い高齢者
や小児が容易に服用することができる。
EFFECTS OF THE INVENTION The solid preparation of the present invention has characteristics excellent in moldability and disintegration property, so that it can be easily taken by elderly people and children with weak swallowing power.

【0034】[0034]

【表1】 [Table 1]

フロントページの続き Fターム(参考) 4C076 AA37 BB22 CC21 DD38 DD67 EE32B FF04 FF06 Continuation of the front page F term (reference) 4C076 AA37 BB22 CC21 DD38 DD67 EE32B FF04 FF06

Claims (6)

【特許請求の範囲】[Claims] 【請求項1】 ゆるめ嵩密度が0.40g/ml以上
で、かつ固め嵩密度が0.60g/ml以上である低置換
度ヒドロキシプロピルセルロース及び糖・糖アルコール
を含有することを特徴とする固形製剤。
1. A solid containing low-substituted hydroxypropylcellulose having a loose bulk density of at least 0.40 g / ml and a hardened bulk density of at least 0.60 g / ml, and a sugar / sugar alcohol. Formulation.
【請求項2】 ゆるめ嵩密度が0.40g/ml以上
で、かつ固め嵩密度が0.60g/ml以上で、かつ乾式
レーザー回折法による体積平均粒子径が30ミクロン以
上である低置換度ヒドロキシプロピルセルロースを粉砕
して得られる該回折法による体積平均粒子径が25ミク
ロン以下の低置換度ヒドロキシプロピルセルロース及び
糖・糖アルコールを含有することを特徴とする固形製
剤。
2. A low-substituted hydroxy resin having a loose bulk density of 0.40 g / ml or more, a hardened bulk density of 0.60 g / ml or more, and a volume average particle diameter of 30 μm or more measured by a dry laser diffraction method. A solid preparation comprising low-substituted hydroxypropylcellulose having a volume average particle size of 25 μm or less obtained by pulverizing propylcellulose and obtained by the diffraction method, and sugar / sugar alcohol.
【請求項3】 上記糖・糖アルコールが、エリスリトー
ル、ソルビトール、トレハロース、キシリトール、マン
ニトール、グルコース、白糖からなる一群から選ばれる
一以上であることを特徴とする請求項1又は2に記載の
固形製剤。
3. The solid preparation according to claim 1, wherein the sugar or sugar alcohol is at least one selected from the group consisting of erythritol, sorbitol, trehalose, xylitol, mannitol, glucose, and sucrose. .
【請求項4】 上記糖・糖アルコールの平均粒子径が、
500ミクロン以下である請求項1〜3のいずれかに記
載の固形製剤。
4. The sugar / sugar alcohol has an average particle diameter of:
The solid preparation according to any one of claims 1 to 3, which has a size of 500 microns or less.
【請求項5】 上記低置換度ヒドロキシプロピルセルロ
ースのヒドロキシプロポキシル基含量が、5.0〜1
6.0重量%であることを特徴とする請求項1〜4のい
ずれかに記載の固形製剤。
5. The low-substituted hydroxypropylcellulose having a hydroxypropoxyl group content of 5.0-1.
The solid preparation according to any one of claims 1 to 4, which is 6.0% by weight.
【請求項6】 固形製剤の製造方法において、ゆるめ嵩
密度が0.40g/ml以上で、かつ固め嵩密度が0.
60g/ml以上である低置換度ヒドロキシプロピルセル
ロースと糖・糖アルコール、又は該低置換度ヒドメキシ
プロピルセルロースであって乾式レーザー回折法による
体積平均粒子径が30ミクロン以上であるものを粉砕し
て得られた体積平均粒子径が25ミクロン以下の低置換
度ヒドロキシプロピルセルロースと該糖・糖アルコール
を混合させることを特徴とする固形製剤の製造方法。
6. A method for producing a solid preparation, wherein the loose bulk density is 0.40 g / ml or more, and the loose bulk density is 0.1 g / ml.
A low-substituted hydroxypropylcellulose and sugar / sugar alcohol that are 60 g / ml or more, or the low-substituted hydroxymexylpropylcellulose having a volume average particle diameter of 30 μm or more measured by a dry laser diffraction method is pulverized. A method for producing a solid preparation, comprising mixing the low-substituted hydroxypropylcellulose having a volume average particle diameter of 25 μm or less with the sugar / sugar alcohol.
JP2001074044A 2000-03-17 2001-03-15 Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same Expired - Fee Related JP3698652B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001074044A JP3698652B2 (en) 2000-03-17 2001-03-15 Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000075092 2000-03-17
JP2000-75092 2000-03-17
JP2001074044A JP3698652B2 (en) 2000-03-17 2001-03-15 Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same

Publications (2)

Publication Number Publication Date
JP2001328948A true JP2001328948A (en) 2001-11-27
JP3698652B2 JP3698652B2 (en) 2005-09-21

Family

ID=26587734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001074044A Expired - Fee Related JP3698652B2 (en) 2000-03-17 2001-03-15 Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same

Country Status (1)

Country Link
JP (1) JP3698652B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133330A1 (en) 2007-04-26 2008-11-06 Toray Industries, Inc. Stable solid preparation comprising 4,5-epoxymorphinan derivative
US8303868B2 (en) 2009-01-26 2012-11-06 Shin-Etsu Chemical Co., Ltd. Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
JP2016026226A (en) * 2010-03-05 2016-02-12 ユニヴァーシティー オヴ ストラスクライド Delayed prolonged drug delivery
US11065205B2 (en) 2010-03-05 2021-07-20 Drug Delivery International Limited Immediate/delayed drug delivery

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2554831T3 (en) * 2009-03-27 2015-12-23 Ykk Corporation Continuous closing element, closing carrier band, and manufacturing process of a continuous closing element

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133330A1 (en) 2007-04-26 2008-11-06 Toray Industries, Inc. Stable solid preparation comprising 4,5-epoxymorphinan derivative
US8420662B2 (en) 2007-04-26 2013-04-16 Toray Industries, Inc. Stable solid preparation containing 4,5-epoxymorphinan derivative
US8303868B2 (en) 2009-01-26 2012-11-06 Shin-Etsu Chemical Co., Ltd. Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
EP3031451A1 (en) 2009-01-26 2016-06-15 Shin-Etsu Chemical Co., Ltd Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
JP2016026226A (en) * 2010-03-05 2016-02-12 ユニヴァーシティー オヴ ストラスクライド Delayed prolonged drug delivery
US11065205B2 (en) 2010-03-05 2021-07-20 Drug Delivery International Limited Immediate/delayed drug delivery

Also Published As

Publication number Publication date
JP3698652B2 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
US4832956A (en) Disintegrating tablet and process for its preparation
TWI271198B (en) Tables disintegrating rapidly in the oral cavity
KR100571085B1 (en) Low-substituted hydroxypropyl cellulose-containing solid preparation and preparation method thereof
JP4748627B2 (en) Excipient
CN101374503B (en) Quickly disintegrating tablet produced by direct dry-tabletting
JP5623275B2 (en) Directly tabletable dextrose
JP2006501234A (en) Use of water-soluble sugar aqueous solutions such as citric acid and lactitol as tableting solutions in tablet production
EP2007384B1 (en) Orodispersible domperidone tablets
RU2500388C2 (en) Orally dispersible mannitol
CN101708336B (en) Novel medicinal premixing auxiliary material
JP5552400B2 (en) Granules masking bitterness and unpleasant taste of herbal medicines and intraoral quick disintegrating tablets
WO2007018057A1 (en) Tablet rapidly disintegrating in the oral cavity and method of producing the same
JP2001322927A (en) Solid preparation including hydroxypropyl cellulose of low substitution degree and method for preparation of the same
JP4015485B2 (en) Antacid / loose tablets
JP3698652B2 (en) Low substituted hydroxypropylcellulose-containing solid preparation and method for producing the same
US6274172B1 (en) Therapeutic effervescent compositions
JP5584509B2 (en) Orally disintegrating tablets
US20130072578A1 (en) Orodispersible tablets of erythritol and isomalt
JP3796848B2 (en) Herbal medicine-containing solid composition
JP2000007555A (en) Tablet and its production
JP2002138055A (en) Intraoral quick disintegration type compression molding and its production method
JP2008133294A (en) Tablet disintegrated in buccal cavity

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20040123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040130

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040330

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20041130

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050127

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050322

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20050329

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050705

R150 Certificate of patent or registration of utility model

Ref document number: 3698652

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080715

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110715

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140715

Year of fee payment: 9

LAPS Cancellation because of no payment of annual fees